drugset / Trial / NCT00325013
Evaluation of DHA for the Treatment of PSC
Phase 1
Completed
10 enrolled
Beth Israel Deaconess Medical Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The researches aim to study the effects of DHA (component of fish oil) on patients with Primary Sclerosing Cholangitis (PSC). Our hypothesis is that DHA might reverse the problems associated with PSC.
Timeline
- Start
- 2005-12
- Primary completion
- 2012-05
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DOCONEXENT | Other / unclassified | 800 mg | Oral |